CSC Pharmaceuticals International

Dose	1ml-5ml
Injectable Form	Solution
Application	Analgesics and Pain Relief Medicines, Anti Infective & Common Disease Medicines
Injection Site	Intravenous, Intramuscular
Packaging Type	Glass Bottle
Packaging Size	10 mg
Medicine Type	Allopathic

We offering a wide range of Reopro 10 Mg Injection to our clients.

Drug Type	Methylprednisolone Sodium Succinate Injection
Packaging Size	1 ml
Packaging Type	Vials
Dose	500 mg
Manufacturer	Pfizer Ltd
Brand Name	Solu Medrol
Usage/Application	As steroid and anti inflammatory drug
Injection Administration type	IV, IM
Composition	Methylprednisolone 500 mg
Usage	Arthritis, Pain and Inflammation, Severe Allergies
Form	Injection
Prescription/Non-Prescription	Prescription
Country of Origin	Made in India

PFIZER   
"SOLU-MEDROL Sterile Powder is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.

The chemical name for methylprednisolone sodium succinate is pregna-1,4-diene-3,20dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-6-methyl-monosodium salt, (6α, 11β), and the molecular weight is 496.53. The structural formula is represented below:

SOLU-MEDROL® (methylprednisolone sodium succinate) Structural Formula Illustration

Methylprednisolone sodium succinate is soluble in water; it may be administered in a small volume of diluent and is well suited for intravenous use in situations where high blood levels of methylprednisolone are required rapidly.

SOLU-MEDROL is available in preservative and preservative-free formulations:"

Dose	5ml-10ml, 1ml-5ml
Injectable Form	Solution
Application	Anti Infective & Common Disease Medicines
Injection Site	Intramuscular, Intravenous
Packaging Type	Glass Bottle
Medicine Type	Allopathic

With the continuous support and sincere efforts put by our experienced professionals, we have been able to provide Remestyp 1.0 Injection.

Manufacturer	Janssen
Brand	Remicade
Treatment	Arthritis
Packaging type	Vial
Composition	Infliximab 100mg/10ml
Strength / Dose	100 mg
Dosage Form	Injection
Grade	Medicine grade

Schering plough
Rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis.

Strength	100mg
Packaging Type	Vial
Packaging Size	1ml
Brand	SOLU-CORTEF
Manufacturer	PFIZER Ltd
Injection Administration type	IM, IV
Usage	Arthritis, Severe Allergies
Prescription/Non-Prescription	Prescription

PFIZER   
"SOLU-CORTEF Sterile Powder is an anti-inflammatory glucocorticoid, which contains hydrocortisone sodium succinate as the active ingredient. SOLU-CORTEF Sterile Powder is available in several packages for intravenous or intramuscular administration.

100 mg Plain - Vials containing hydrocortisone sodium succinate equivalent to 100 mg hydrocortisone, also 0.8 mg monobasic sodium phosphate anhydrous, 8.73 mg dibasic sodium phosphate dried. SOLU-CORTEF 100 mg plain does not contain diluent (see DOSAGE AND ADMINISTRATION, Preparation of Solutions)."

Injectable Form	Solution
Application	Anti Infective & Common Disease Medicines
Packaging Size	5 mg
Injection Site	Intravenous
Packaging Type	Glass Bottle
Medicine Type	Allopathic
Dose	1ml-5ml

We are the remarkable entity, engaged in offering the superior quality range of Zavedos 5Mg Injection.

Strength	200 mg
Packaging size	10 ml
Packaging type	Vial

ALTANA PHARMA   
"Venofer (iron sucrose injection, USP), an iron replacement product, is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use. Iron sucrose injection has a molecular weight of approximately 34,000 to 60,000 daltons and a proposed structural formula: [Na2Fe5O8(OH) •3(H2O)]n •m(C12H22O11) where: n is the degree of iron polymerization and m is the number of sucrose molecules associated with the iron (III)-hydroxide. Each mL contains 20 mg elemental iron as iron sucrose in water for injection. Venofer is available in 10 mL single-use vials (200 mg elemental iron per 10 mL), 5 mL single-use vials (100 mg elemental iron per 5 mL), and 2.5 mL single-use vials (50 mg elemental iron per 2.5 mL). The drug product contains approximately 30% sucrose w/v (300 mg/mL) and has a pH of 10.5 to 11.1. The product contains no preservatives. The osmolarity of the injection is 1,250 mOsmol/L."   
ONCOLOGY

Dose/Strength	20 mg
Packaging Type	Glass Ampoules
Dosage Form	Injection

We are amongst the most reputed names in the industry, offering Dantrolene Sodium Injection.

SANOFI AVENTIS   
"PRIMACOR™ 3003 Copolymer is an ethylene acrylic acid copolymer which has been specifically designed by Dow for use as an adhesive or sealant layer in extrusion coating and extrusion lamination. PRIMACOR 3003 Copolymer exhibits:  Excellent draw-down and edge stability     Excellent organoleptic properties Excellent toughness and strength Outstanding environmental stress crack and product resistance Excellent hot-tack and sealability Adhesion to paper, paperboard, metals and polyethylenes Insensitivity to moisture"   
PNEUMONIA VACCINE

CHIRON NOVARTIS   
"nterleukin -2 (aldesleukin, [Proleukin®]) is a cytokine with the following immune-modulating effects: enhancement of lymphocyte mitogenesis and cytotoxicity, induction of lymphocyte-
activated (LAK) cells and natural killer (NK) cells, and induction of gamma production. U.S. Food and Drug Administration (FDA)-approved labeled indications include the treatment of metastatic renal cell carcinoma and metastatic malignant melanoma. Other oncologic applications of IL-2 monotherapy are being actively investigated, principally as a technique
to maintain remission or eliminate minimal residual disease in patients with a variety of malignancies, including most prominently leukemias, but also including lymphomas and other solid tumors such as neuroblastoma and breast cancer. IL-2 has also been used post-autologous bone marrow transplantation as an immunotherapeutic technique to maintain remission and reduce the relapse rate. In HIV -infected patients, there is a reduced endogenous production of IL-2 and a defect in IL -2 receptor expression, respon  sible in part for the characteristic reduction in CD4 counts. Exogenous IL-2, in conjunction with antiretroviral therapy, has been investigated as atechnique to increase CD4 counts, preserve immune function and hopefully decrease the incidence of opportunistic infections. It has been proposed that IL-2 in conjunction with combination antiretroviral therapy may be a useful approach for purging HIV from the latently infected CD4 cells. IL-2 has also been investigated as a component of a variety of combinat ion therapies, for example in combination with alpha in the treatment of metastatic renal cell cancer and metastatic melanoma. IL-2 can be administered by subcutaneous injection (low-dose therapy) or into a vein (intermediate or high
-dose thera py), either intermittently as a bolus or quick injection, or as a continuous treatment over a defined period of time"   
ONCOLOGY

CHIRON VACCINES   
"RABIPUR ® Product Information AUSTR 100582 Page 1 of 13 Version 2.0 RABIPUR ® Inactivated Rabies Virus Vaccine DESCRIPTION RABIPUR ® is an inactivated rabies virus vaccine, derived from the fixed -virus strain, Flury LEP. The virus is propagated in aPurified Chick Embryo Cell
(PCEC) culture, inactivated using - propiolact one and purified viacentrifugation. It is supplied in a single - dose presentation consisting of a vial containing lyophilised powder (vaccine component), accompanied by an ampoule of diluent (Water for Injections). Each 1.0mL dose of the reconstituted vaccine contains no less than 2.5IU of inactivated rabies virus, in accordance with the World Health Organisation requirements. Each 1.0mL dose of the reconstituted vaccine also contains the following excipients: trometamol (3.5mg), sodium chloride (4.5mg) , disodium edetate (0.25mg), monopotassium glutamate (0.9mg), polygeline (10.5mg), sucrose (60mg) and water for injections (1.0mL). The quantities of each excipient  (excluding water for injection) will vary dependent on virus concentration in the harvested material. The  neomycin, chlortetracycline and amphotericin B are used in the manufacturing process of this vaccine and may be present in trace amounts. The manufacture of this product includes exposure to bovine derived materials. No evide nce exists that any case of vCJD (considered to be the human form of bovine spongiform encephalitis) has resulted from the administration of any vaccine product"   
RABIES VACCINE

GSK  
"TYPHERIX Product Information 1 (8) Issue No. 5 1 TYPHERIX PRODUCT INFORMATION (Salmonella typhiVi polysaccharide) DESCRIPTION TYPHERIX is a colourless, sterile liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2 strain.
The production of Vi polysaccharide active ingredient involves fermentation of S.typhi bacteria followed by extraction/purification of the Vi polysaccharide. Traditional culture methods are used for fermentation of S.typhi. Each 0.5 ml dose of vaccine contains 25 μg of the Vi polysaccharide of Salmonella typhi in a sterile isotonic sodium chloride solution. TYPHERIX contains phenol (as preservative), and a phosphate buffer. The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. TYPHERIX meets the World Health Organisation (WHO) requirements for biological
substances and conforms with the European Pharmacopoeia monograph on Vipolysaccharide typhoid vaccines. No substance of human origin is used in its manufacture."   
TYPHOID VACCINE

SANOFI PASTEUR
yphim Vi®, Typhoid Vi Polysaccharide Vaccine, produced by Sanofi Pasteur SA, for intramuscular use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S. typhi Ty2 strain. The organism is grown in a semisynthetic medium. Casein derived raw materials are used early in manufacturing during the fermentation process. The capsular polysaccharide is precipitated from the concentrated culture supernatant by the addition of hexadecyltrimethylammonium bromide, and the product is purified by differential centrifugation and precipitation. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg) used for the inactivation of the bacterial culture. The potency of the purified polysaccharide is assessed by molecular size and O-acetyl content. Phenol, 0.25%, is added as a preservative. The vaccine contains residual polydimethylsiloxane or fattyacid ester-based antifoam. The vaccine is a clear, colorless solution. Each dose of 0.5 mL is formulated to contain 25 mcg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7 ± 0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, and 0.5 mL of Sterile Water for Injection.  
TYPHOID VACCINE

ELI LILLY   
"Xigris (drotrecogin alfa (activated)) is a recombinant form of human activated protein C. An established human cell line possessing the complementary DNA for the inactive human protein C zymogen secretes the protein into the fermentation medium. Fermentation is carried out in a nutrient medium containing the antibiotic geneticin sulfate. Geneticin sulfate is not detectable in the final product. Human protein C is enzymatically activated by cleavage with thrombin and subsequently purified. Drotrecogin alfa (activated) is a serine protease with the same amino acid sequence as human plasma-derived activated protein C. Drotrecogin alfa (activated) is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa (activated) and human plasma-derived activated protein C have the same sites of glycosylation, although some differences in the glycosylation structures exist.Xigris (drotrecogin alfa) is supplied as a sterile, lyophilized, white to off-white powder for intravenous infusion. The 5 and 20 mg vials of Xigris contain 5.3 mg and 20.8 mg of drotrecogin alfa (activated), respectively. The 5 and 20 mg vials of Xigris (drotrecogin alfa) also contain 40.3 and 158.1 mg of sodium chloride, 10.9 and 42.9 mg of sodium citrate, and 31.8 and 124.9 mg of "   
SEVERE ADULT SEPSIS